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Somatic mutations in spliceosome genes are found in 50% of patients with myelodysplastic syndromes
(MDS), a myeloid malignancy associated with low blood counts. Expression of the mutant splicing factor
U2AF1(S34F) alters hematopoiesis andmRNA splicing inmice. Our understanding of the functionally relevant
alternatively spliced target genes that cause hematopoietic phenotypes in vivo remains incomplete. Here, we
demonstrate that reduced expression of H2afy1.1, an alternatively spliced isoform of the histone H2A variant
gene H2afy, is responsible for reduced B cells in U2AF1(S34F) mice. Deletion of H2afy or expression of
U2AF1(S34F) reduces expression of Ebf1 (early B cell factor 1), a key transcription factor for B cell develop-
ment, and mechanistically, H2AFY is enriched at the EBF1 promoter. Induced expression of H2AFY1.1 in
U2AF1(S34F) cells rescues reduced EBF1 expression andBcells numbers in vivo. Collectively, our data impli-
cate alternative splicing ofH2AFY as a contributor to lymphopenia induced byU2AF1(S34F) inmice andMDS.
INTRODUCTION
Myelodysplastic syndromes (MDS) are the most common
myeloid cell malignancies in adults. MDS are a heterogenous
group of clonal hematopoietic stem cell disorders characterized
by ineffective hematopoiesis leading to low blood counts,
including B lymphopenia, and dysplasia of one or more hemato-
poietic cell lineages. Sequencing studies have identified recur-
rent somatic mutations in spliceosome genes (most commonly
in SF3B1, SRSF2, U2AF1, and ZRSR2) in over half of MDS pa-
tients (Damm et al., 2012; Graubert et al., 2011; Papaemmanuil
et al., 2011; Thol et al., 2012; Visconte et al., 2012; Yoshida
et al., 2011). Using genetically engineered mouse models, we
and others have reported that expression of common spliceo-
some gene mutants—including U2AF1(S34F), SRSF2(P95H),
and SF3B1(K700E)—leads to alterations in RNA splicing and he-
matopoiesis in mice, including a reduction of mature hematopoi-
etic cells, recapitulating features of human MDS (Fei et al., 2018;
Kim et al., 2015b; Kon et al., 2018; Mupo et al., 2017; Obeng
et al., 2016; Shirai et al., 2015; Smeets et al., 2018).
Whether alternative splicing of specific target RNAs by mutant
splicing factors causes hematopoietic phenotypes and/or con-
tributes to MDS pathogenesis is an active area of research.
Splicing of H2AFY, ATG7, and STRAP (by U2AF1[S34F]) or
Ezh2 (by SRSF2[P95H]) was shown to be dysregulated in
splicing factor mutant cells. Altering the splicing of these target
genes can recapitulate or rescue the mutant-splicing-factor-
induced phenotypes in vitro (Kim et al., 2015b; Park et al.,
2016; Yip et al., 2017). However, it remains to be tested whether
U2AF1 mutant-induced splicing changes directly contribute to
altered hematopoiesis in vivo or are simply a biomarker of spli-
ceosome gene mutations without functional significance.
H2AFY (also known as macroH2A1) is a histone H2A variant
gene that has a role in metabolic functions, transcriptional
gene regulation, and DNA damage response (Boulard et al.,
2010; Changolkar and Pehrson, 2006; Changolkar et al., 2010;
Gamble et al., 2010; Posavec Marjanovic et al., 2017). H2AFY
encodes two splice isoforms, H2AFY1.1 and H2AFY1.2 (also
known as macroH2A1.1 and macroH2A1.2, respectively), and
alternative splicing induced by U2AF1(S34F) expression leads
to reductions in the H2AFY1.1 isoform (Fei et al., 2018; Ilagan
et al., 2015; Shirai et al., 2015; Yip et al., 2017). Reduced expres-
sion of H2AFY1.1 has also been reported in a variety of solid tu-
mors (Li et al., 2016; Novikov et al., 2011; Sporn and Jung, 2012;
Sporn et al., 2009). In addition, Bereshchenko et al. (2019)
recently reported that mice lacking H2AFY1.1 showed altered
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Figure 1. H2afy is a target gene of U2AF1(S34F)-induced alternative splicing
(A) Expression of U2AF1(S34)-induced alternatively spliced isoforms in eight genes in common myeloid progenitors (CMPs), monocytes (MONO) and B cells in
mice were examined using a Nanostring assay. Log2-fold change of U2AF1(S34F) samples compared to U2AF1(WT) samples are shown (n = 2–9 biologic
replicates per tissue).
(B) Diagram showing two H2AFY splice isoforms, H2AFY1.1 and H2AFY1.2.
(C–G) Whole bone marrow cells from H2afy+/+, H2afy+/ and H2afy/ littermates were transplanted into lethally irradiated WT congenic recipient mice. (C)
Overview of the non-competitive bone marrow transplant assay. (D) Peripheral bloodWBCs at 4 months post-transplant (n = 13–17). (E) Peripheral blood lineage
(legend continued on next page)




hematopoiesis, including increasedmyeloid cells and decreased
B cells. However, whether reduced H2afy1.1 expression is
responsible for U2AF1(S34F)-induced hematopoietic pheno-
types in vivo remains to be determined. In this study, we investi-
gated whether alternative splicing of H2AFY contributes to he-
matopoietic phenotypes and MDS pathogenesis in patients
expressing mutant U2AF1(S34F).
RESULTS
H2afy is a target gene of U2AF1(S34F)-induced
alternative splicing
We previously reported that expression of U2AF1(S34F) results
in hematopoietic phenotypes, including increased hematopoiet-
ic stem/progenitor cells, increased monocytes, and reduced B
cells inmice (Shirai et al., 2015).We hypothesized that alternative
splicing of specific target genes induced by U2AF1(S34F)
directly contributed to hematopoietic phenotypes. To address
the hypothesis, we analyzed three available RNA sequencing
(RNA-seq) datasets that compared wild-type (WT) U2AF1 versus
mutant U2AF1 samples (cultured human CD34+ cells [Okeyo-
Owuor et al., 2015], mouse common myeloid progenitors
(CMPs) [Shirai et al., 2015], and human acute myeloid leukemia
samples [Ley et al., 2013]) and identified 13 genes that showed
similar alternative splicing across the three RNA-seq datasets
(Shirai et al., 2015). We designed probes to interrogate iso-
form-specific expression for 8 of the 13 genes; 5 genes were
not tested due to technical difficulties. Nanostring analysis
orthogonally validated alternative splicing of these target genes
in mouse CMPs, monocytes, and B cells—the hematopoietic
cell types that are altered by U2AF1(S34F) expression in mice
(Figure 1A). Expression of all 8 isoforms was significantly altered
in mouse CMPs (false discovery rate [FDR] < 0.1), with variable
alterations in the monocytes and B cells. H2afy had consistent
alternative splicing in all the three cell types, with greater than
a 2-fold reduction in H2afy1.1 isoform expression in
U2AF1(S34F) mutant cells (Figure 1A). The two splice isoforms
ofH2afy—H2afy1.1 andH2afy1.2—share all but exon 6 (mutually
exclusive use of exon 6) (Figure 1B). Based on these lines of ev-
idence, we hypothesized that alternative splicing of H2AFY
contributed to the U2AF1(S34F)-induced hematopoietic pheno-
types and MDS pathobiology. We addressed this hypothesis in
three steps. First, we characterized H2afy/ mice to delineate
the role of H2afy in normal hematopoiesis. Second, we per-
formed a complementation assay by re-expressing H2AFY1.1
inH2afy/ hematopoietic cells to identify H2AFY1.1-dependent
hematopoietic phenotypes. Third, we determined whether
H2AFY1.1 expression can rescue altered hematopoiesis in
U2AF1(S34F) mutant mice by re-expressing H2AFY1.1 in
U2AF1(S34F) hematopoietic cells.
H2afy knockout mice carry a constitutive deletion of exon 2
and lack expression of both H2afy1.1 and H2afy1.2 isoforms
(Changolkar et al., 2007). H2afy knockout mice are viable, born
at the expected Mendelian frequency, and have reduced or ab-
sent H2AFY protein expression in H2afy+/ and H2afy/ bone
marrow cells, respectively (Figure S1A). To study the hematopoi-
etic-cell-intrinsic effect of H2afy loss in mice (including both
H2afy1.1 and H2afy1.2 isoforms), we transplanted donor bone
marrow cells from H2afy+/+, H2afy+/, and H2afy/ littermate
mice into lethally irradiated congenic recipients (Figure 1C). At
4 months post-transplant, H2afy/ recipients had reduced pe-
ripheral blood white blood cell counts (WBCs) (Figure 1D). In
the peripheral blood, bone marrow, and spleen of recipient
mice, we observed a reduction in H2afy+/ and H2afy/ B cells
in a gene dose-dependent manner, but normal monocytes and
hematopoietic stem and progenitor numbers, including CMPs,
in null mice (Figures 1E, 1F, S1B, and S1C). These data suggest
that reduced expression ofH2afy1.1 contributes to lower mature
B cell numbers but not to the CMP and monocyte phenotypes
observed in U2AF1(S34F) mice. Next, we assessed the bone
marrow B cell progenitor numbers in H2afy+/+, H2afy+/, and
H2afy/ mice using a methylcellulose colony forming unit
(CFU) assay (CFU-pre-B). Relative to H2afy+/+ mice, H2afy+/
and H2afy/ mice had reduced CFU-pre-B colony numbers
(Figure 1G) but preserved myeloid CFUs (CFU-C; data not
shown). Reduced CFU-pre-B numbers suggested a functional
defect of B cell progenitors with H2afy loss. Next, we examined
the stem/progenitor cell function of H2afy-deficient cells using a
competitive repopulation assay.
H2afy/ mice have defective B cell development in the
bone marrow
We focused on comparing H2afy/ hematopoietic cells to WT
control cells because H2afy/ hematopoietic cells are an ideal
platform to perform complementation assays for re-expressing
the individual H2afy splice isoforms to study their role in hemato-
poiesis. Test bone marrow cells (CD45.2+) from H2afy+/+ or
H2afy/mice weremixedwith an equal number ofWT congenic
competitor cells (CD45.1+/45.2+) and transplanted into lethally
irradiated congenic recipient mice (CD45.1+) (Figure 2A). The
competitive repopulation assays revealed a disadvantage for
H2afy/ stem/progenitor cells compared toH2afy+/+ cells in pri-
mary recipient mice based on peripheral blood chimerism (Fig-
ure 2B). The competitive disadvantage of H2afy/ donor cells
was largely due to reductions in H2afy/ B cells in the bone
marrow, peripheral blood, and spleen of recipient mice (Figures
2C, S2A, and S2B). H2afy/ bone marrow monocytes, neutro-
phils, and hematopoietic stem and progenitor cells also showed
significant but modest reductions in recipient mice (Figures 2C
and S2C). Given the significant reductions in H2afy/ donor-
cell-derived mature B cells, we examined B cell development
in these mice. While B cell progenitors—including all-lymphoid
progenitors (ALPs), B-cell-biased lymphoid progenitors
(BLPs), and Hardy fraction A (also known as pre-pro B cells)
cell counts at 4months post-transplant (n = 13–17). (F) Bonemarrow lineage cell frequencies at 12months post-transplant (n = 5–15). (G) Pre-B cell colonies in the
CFU-pre-B assay (n = 10–16).
Data are shown as fold change of colonies ofH2afy+/ orH2afy/ pre-B cells relative toH2afy+/+ colonies. Statistical analysis by two-tailed Student’s t test. Error
bars represent mean ± SD. ns, not significant; *p < 0.05, **p < 0.01, ***p < 0.001.




(Hardy et al., 1991)—were no different between H2afy+/+ and
H2afy/ cells, we observed marked reductions in all stages
from H2afy/ pro-B cells through mature B cells (Figure 2D).
Next, we examined whether U2AF1(S34F) mice had similar B




















































































































Figure 2. H2afy/ mice have defective B cell development
A competitive repopulation assaywas performed by transplanting bonemarrow cells fromH2afy+/+ orH2afy/ littermates (CD45.2+) with the same number ofWT
congenic competitor marrow cells (CD45.1+/CD45.2+) into lethally irradiated congenic recipients (CD45.1+).
(A) Overview of the competitive repopulation assay.
(B) Peripheral blood chimerism of CD45.2+ cells at 1, 2, and 4 month(s) post-transplant (n = 16). Differences (two-way ANOVA) are indicated at each time point.
(C) CD45.2+ bone marrow lineage cell frequencies at 4 months post-transplant (n = 7).
(D) Donor-derived CD45.2+ B cell progenitors (ALP and BLP) and Hardy fractions (n = 7).
Statistical analysis by two-tailed Student’s t test, except for (B). Error bars represent mean ± SD. ns, not significant; *p < 0.05, **p < 0.01, ***p < 0.001.




U2AF1(S34F) expression induces defective B cell
development similar to H2afy loss
We examined whether the B cell developmental defects
observed in H2afy-null mice occur in U2AF1(S34F) mice, which
have reduced expression of the H2afy1.1 isoform (Shirai et al.,
2015). Because our previous study investigated the effect of
U2AF1(S34F) expression in a mixed genetic background,
we backcrossed the doxycycline-inducible U2AF1(WT) and
U2AF1(S34F) transgenic mice to C57BL/6 mice at least 10
times (hereafter, we refer to these mice as U2AF1(WT)
andU2AF1(S34F) mice, respectively). To explore the hematopoi-
etic-cell-intrinsic effect of U2AF1(S34F) expression on B cell
development, we transplanted bone marrow cells from U2AF1
(WT) or U2AF1(S34F) mice into lethally irradiated congenic recip-
ients. Expression of U2AF1(S34F) led to significant reductions in
WBCs, peripheral blood B cells, and bone marrow B cells in
recipient mice compared to U2AF1(WT) expression (Figures
3A–3C). In addition, U2AF1(S34F) expression led to defective B
cell development characterized by reduced pro-B through
mature B cells (Figure 3D), similar to that observed in H2afy/
mice. CFU-pre-B colony numbers were also reduced in
U2AF1(S34F) compared to U2AF1(WT) recipients (Figure 3E),
corroborating defective B cell development with U2AF1(S34F)
expression. Collectively, the data demonstrate that U2AF1
(S34F) expression leads to defective B cell development similar
to H2afy loss.
Ebf1 expression is reduced in H2afy/ BLPs
Next, we investigated the mechanism underlying the defect in
maturation from H2afy/ pre-pro-B cells to pro-B cells—the
first step of B cell differentiation defect uponH2afy loss. Because































































































































































Figure 3. U2AF1(S34F) expression induces defective B cell development
Analysis of recipient mice transplanted with bone marrow cells from transgenic U2AF1(WT) or U2AF1(S34F) mice following 1 month of doxycycline induction
(n = 10).
(A) Peripheral blood WBC count.
(B) Peripheral blood B cell counts.
(C) Bone marrow B cell counts.
(D) Frequencies of B cell progenitors (ALP and BLP) and Hardy fractions.
(E) The number of pre-B cell colonies in the CFU-pre-B assay.
Statistical analysis by two-tailed Student’s t test. Error bars represent mean ± SD. ns, not significant; *p < 0.05, **p < 0.01, ***p < 0.001.
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expression (Changolkar and Pehrson, 2006; Changolkar et al.,
2010), we hypothesized that H2AFY transcriptionally regulates
expression of a critical gene(s) involved in B cell development.
To address this possibility, we performed RNA-seq on immuno-
phenotypically defined bone marrow BLPs from H2afy+/+ and
H2afy/ mice (Figures 4A and S4A). BLPs were selected
because they are immediately upstream of the affected pro-B
cells, and BLPs express high levels of H2afy RNA (RNA-seq
data from the ImmGen consortium; Heng et al., 2008) (Figure S3).
First, we confirmed the expected lack of H2afy exon 2 expres-
sion in H2afy/ samples (Figure 4B). Next, we identified 214
differentially expressed genes (DEGs) with FDR < 0.1 between
H2afy+/+ and H2afy/ cells (Figure 4C; Table S1). The 214
DEGs segregated samples according to their genotypes, as ex-
pected (Figure 4C). Among the DEGs, we discovered that early B
cell factor 1 (Ebf1), a transcription factor critical for early B cell
development, was downregulated in H2afy/ BLPs (Figure 4D).
In addition, downregulated DEGs were enriched in cell-cycle-
and mitosis-associated pathways, and upregulated genes
were involved in interferon signaling and the unfolded protein
response (Table S2). We validated that the RNA and protein
expression of Ebf1 were reduced in H2afy/ cells using qRT-
PCR (Figure 4E) and intracellular flow cytometry (Figures 4F
and S5A), respectively. In addition to reduced Ebf1 expression,
we found that known downstream targets of EBF1 were downre-
gulated inH2afy/ BLPs, including transcription factors (Foxo1,
Lef1, Id3), and genes involved in V(D)J recombination (Rag1) and
B cell functions (Cd19, Vpreb2, Blnk, etc.) (Figure 4D).
To examine the significance of reduced EBF1 expression upon
H2afy loss, we compared the list of DEGs in H2afy/ BLPs to
known Ebf1 targets genes identified in Ebf1/ pre-pro-B cells
(Jensen et al., 2018) and identified a significant overlap of 126
concordant DEGs between the two datasets (59%, p < 0.001),
many with important functions for B cell development and/or
function (Figure S4B; Table S3). Furthermore, the B cell pheno-
type of H2afy/ mice (that have 2-fold reduction in EBF1
levels) was similar to Ebf1+/ mice that have a reduction in pro-
B throughmature B cell stages, but not in ALPs or BLPs (Âhsberg
et al., 2013). Collectively, the results suggested that reduced
expression of Ebf1 might be responsible for the defective B
cell development of H2afy/ B cell progenitors.
To study the mechanism whereby H2AFY regulates Ebf1
expression, we examined the occupancy of H2AFY at the pro-
moter of Ebf1 by chromatin immunoprecipitation followed by
qPCR, as previously described (Jiang et al., 2011). To measure
occupancy of H2AFY at the Ebf1 promoter in the context of early
B cell development, we createdWT andH2afy/ pre-B cell lines
by transforming H2afy+/+ and H2afy/ bone marrow cells with
Abelson murine leukemia virus, respectively (Bredemeyer et al.,
2006; Mainville et al., 2001). H2AFY enrichment at the Ebf1 pro-
moter, A-D regions, was significantly higher in the H2afy+/+
compared to the H2afy/ pre-B cell samples (Figure 4G). The
data suggested that H2AFY was present at the promoter of
Ebf1 to regulate its expression. Taken together, the data demon-
strated that H2afy/ BLPs had reduced Ebf1 and EBF1 target
gene expression, suggesting that reducedEbf1expressionmight
contribute to the defective H2afy/ B cell development.
Expression of H2AFY1.1 in H2afy/ bone marrow cells
rescues reduced B cells in vivo
We next asked which H2afy isoform, H2afy1.1 or H2afy1.2, was
important for the defective B cell development as H2afy/ mice
lacked both isoforms. To address this question, we performed
complementation assays by virally expressing either the
H2AFY1.1 or H2AFY1.2 isoform in c-Kit-enriched H2afy/
bone marrow cells, transplanting cells into lethally irradiated
congenic recipients, andmonitoring B cells (Figure 5A). Because
human and mouse H2AFY are 98% identical at the amino acid
level, and the exons specific to H2afy1.1 or 1.2 isoforms are
conserved, we expressed human H2AFY1.1 or H2AFY1.2 in
H2afy/ mouse bone marrow cells. We first determined the ef-
fect of H2AFY isoform expression on B cell development by
measuring the frequency of functional common lymphoid pro-
genitors (CLPs) ex vivo. At 4 months post-transplant, GFP+
CLPs (i.e., transduced cells) were sorted at limiting dilutions in
96-well plates with an OP9 feeder layer and cultured for
1 week in the presence of mouse IL7 (interleukin 7). Expression
ofH2AFY1.1 significantly increased the frequencies of functional
CLPs that produced B cell progeny relative to control or
H2AFY1.2 expression, while expression of H2AFY1.2 only
modestly increased the frequencies of functional CLPs relative
to control expression (Figure 5B). We next examined the in vivo
effect of H2AFY1.1 or H2AFY1.2 expression in H2afy-null cells.
Analysis of GFP+ cells in the peripheral blood (Figure 5C) and
the bone marrow (Figure 5D) 4 months post-transplant showed
a significant increase in B cells following H2AFY1.1 expression.
These complementation assay results suggested that the
H2AFY1.1 isoform played a major and important role in B-lym-
phopoiesis in vivo.
Expression of H2AFY1.1 in U2AF1(S34F) bone marrow
cells rescues reduced B cells in vivo
Next, we asked whether exogenousH2AFY1.1 expression could
rescue the B cell phenotype associated with reduced H2afy1.1
Figure 4. Ebf1 expression is reduced in H2afy/ BLPs
(A) Schematic of BLP RNA-seq (n = 4).
(B) Read counts against exon 2 of H2afy.
(C) Heatmap showing 214 DEGs (FDR < 0.1).
(D) Ebf1 and its target gene expression in the BLP RNA-seq data. Log2-fold change of Ebf1 and its target gene RNA expression from RNA-seq data is shown.
(E) Changes in Ebf1 expression upon H2afy loss. A fold change of RNA expression of Ebf1 relative toGapdh in sorted BLPs was determined by qRT-PCR (n = 5).
(F) EBF1 protein expression by intracellular flow cytometry. A fold change of mean fluorescence intensity (MFI) is indicated (n = 5).
(G) Enrichment of H2AFY at the promoter of Ebf1 in WT (H2afy+/+) and H2afy/ pre-B cell lines measured by chromatin immunoprecipitation followed by qPCR
(n = 4).
Statistical analysis by two-tailed Student’s t test. Error bars represent mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001.




expression in U2AF1(S34F) mice. We expressed H2AFY1.1 or
H2AFY1.2 in c-Kit-enriched U2AF1(S34F) bone marrow cells
and transplanted them into lethally irradiated congenic recipi-
ents (Figure 6A). Following engraftment of transduced cells, we
induced U2AF1(S34F) expression with doxycycline treatment.
Flow cytometric analysis of the peripheral blood of control,
H2AFY1.1, and H2AFY1.2 recipients before doxycycline treat-
ment (i.e., before inducing U2AF1(S34F) expression) revealed
no differences in hematopoietic lineage distribution of cells,
including B cells (Figure S6A). We also verified physiologic
A B























































































































Control 1/240 1/115 1/502
H2AFY1.1 1/21 1/14 1/31
H2AFY1.2 1/83 1/54 1/129
Figure 5. Expression of H2AFY1.1 in H2afy/ bone marrow cells rescues reduced B cells ex vivo and in vivo
H2afy/ bone marrow cells were transduced with control lentivirus (GFP alone), H2AFY1.1-, or H2AFY1.2-expressing lentivirus that co-expressed GFP and
transplanted into lethally irradiated congenic CD45.1+ recipients.
(A) Overview of the experimental design.
(B) Limiting dilution assay of functional CLPs (GFP+). Top panel: percent negative wells are plotted against the number of cells seeded per well. Bottom table:
quantification of frequencies of functional CLPs with 95% confidence intervals. Data were pooled from four independent experiments, each consisting of 12–24
replicates.
(C) Peripheral blood GFP+ lineage cells at 4 months post-transplant (n = 8–10).
(D) Bone marrow GFP+ B cells at 4 months post-transplant (n = 5–7).
Statistical analysis by two-tailed Student’s t test, except for (B). Error bars represent mean ± SD. ns, not significant; *p < 0.05, **p < 0.01, ***p < 0.001.




expression of exogenously expressed H2AFY1.1 or H2AFY1.2
relative to endogenous H2AFY (Figure S6B). A decrease in pe-
ripheral blood B cells numbers induced by expression
of U2AF1(S34F) was abrogated by H2AFY1.1 expression
compared to control transduced cells (Figures 6B and S6A).
Similarly, the number of CFU-pre-B colonies was also increased
inH2AFY1.1-expressing bone marrow cells compared to control
or H2AFY1.2-expressing bone marrow, indicating exogenous
H2AFY1.1 expression rescued B cell development in U2AF1
(S34F) bone marrow cells (Figure 6C).
Next, we assessed whether EBF1 expression was altered in
U2AF1(S34F) B cells by intracellular flow cytometric analysis.
U2AF1(S34F) expression reduced the number of B220lowEBF1+
B cells (Figure 6D), and expression of H2AFY1.1 in
U2AF1(S34F)-expressing cells ameliorated the reduction in
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Figure 6. Expression of H2AFY1.1 in U2AF1(S34F) bone marrow cells rescues reduced B cells ex vivo and in vivo
In (A)–(C) and (E), bonemarrow cells from transgenic U2AF1(S34F)mice were transducedwith control lentivirus (GFP alone),H2AFY1.1-, orH2AFY1.2-expressing
lentivirus that co-expressed GFP and transplanted into lethally irradiated congenic CD45.1+ recipients. Recipient mice were treated with doxycycline for
6 months.
(A) Overview of the experimental design.
(B) Peripheral blood GFP+ lineage cells after 6 months of transgene induction with doxycycline (n = 7–10).
(C) CFU-pre-B counts of sorted GFP+ bone marrow cells (n = 5).
(D) Following 1 month of doxycycline induction, B220lowEBF1+ cells in the bone marrow of U2AF1(WT) and U2AF1(S34F) mice were measured by flow cytometry
(n = 4–5). Data are shown as fold change of the U2AF1(WT) samples relative to the U2AF1(S34F) samples.
(E) GFP+B220lowEBF1+ cells were measured by flow cytometry after 6 months of transgene induction (n = 3).
Data are shown as fold change of H2AFY1.1-expressing samples relative to control samples (GFP+). Statistical analysis by two-tailed Student’s t test. Error bars
represent mean ± SD. ns, not significant; *p < 0.05, **p < 0.01, ***p < 0.001.




to U2AF1(S34F) mice, bone marrow samples fromMDS patients
with mutant U2AF1(S34F/Y) have reduced pro-B cells, pre-BI,
pre-BII cells, and B cells and reduced EBF1 levels in CLPs
compared to healthy donor samples (Figures S6C–S6E and
S5B; Table S4). Collectively, the data suggested that reduced
expression of H2AFY1.1 by U2AF1(S34F) might drive B cell phe-
notypes via reduced EBF1 expression.
DISCUSSION
In this study, we demonstrate that alternative splicing of H2afy
contributes to abnormal hematopoiesis induced by U2AF1
(S34F) expression in vivo. H2afy knockout mice and transgenic
U2AF1(S34F) mice share defective B-lymphopoiesis that is
associated with reduced levels of EBF1, a master transcription
factor necessary for B cell development. Our data support that
H2AFY is present at the Ebf1 promoter to regulate its expression
and its downstream targets, many of which are important for
normal B cell development. Furthermore, B cell frequencies
and EBF1 levels are reduced in MDS samples with U2AF1
(S34F) mutations compared to healthy controls. Re-expression
of H2AFY1.1 rescues the reduction in B cells in both H2afy/
and U2AF1(S34F) murine bone marrow cells in vivo, validating
that alternative splicing ofH2afy by U2AF1(S34F) is a functionally
significant splicing event that regulates B cell development.
Collectively, our data implicate alternative splicing of H2AFY as
a contributor to lymphopenia in U2AF1(S34F) mutant MDS
patients.
Multiple mechanisms exist for how spliceosome gene muta-
tions contribute to MDS disease pathogenesis. These include
R-loop formation (Chen et al., 2018; Nguyen et al., 2017,
2018; Singh et al., 2020), alterations in the kinetics of splicing
(Coulon et al., 2014), and alternative splicing (Kim et al.,
2015b; Park et al., 2016; Yip et al., 2017). However, whether
these mechanisms contribute to altered hematopoiesis in vivo
is not known. Here, we provide evidence that alternative
splicing induced by a mutant spliceosome gene directly con-
tributes to abnormal blood counts in vivo, in addition to being
a biomarker. Because our data show that H2afy alternative
splicing accounts for defective B-lymphopoiesis in
U2AF1(S34F) mice, other alternatively spliced targets may be
responsible for the additional hematopoietic phenotypes
observed in U2AF1(S34F) mice, including reduced monocytes
and expanded CMPs. While reduction of H2AFY1.1 in human
hematopoietic cells has also been implicated in altered
erythroid and granulocyte/monocyte differentiation in vitro
(Yip et al., 2017), we did not observe alterations in the develop-
ment of those cell types in H2afy/ mice, suggesting that a
compensation may occur in the constitutive knockout mouse
model, or there are differences due to in vitro versus in vivo
models, or a species difference. Recently, Bereshchenko
et al. (2019) described an H2afy1.1-specific knockout model,
where the authors observed an increase in the frequency of
MAC1+ myeloid cells and a reduced frequency of B cells in
H2afy1.1 knockout mice. Because the absolute number of
MAC1+ myeloid or B cells was not reported, it is unclear
whether loss of H2afy1.1 affects the distribution of hematopoi-
etic lineages or the absolute number of affected lineage cells.
Overall, these findings are consistent with our in vivo H2afy-
null cell complementation assay results, suggesting that the
H2AFY1.1 isoform is the major contributor to B-lymphopoiesis
in vivo.
Isoform switching between H2AFY splice isoforms
H2AFY1.1 and H2AFY1.2 has been appreciated in many
cellular development and tumorigenesis processes (Dardenne
et al., 2012; Dell’Orso et al., 2016; Hodge et al., 2018; Novikov
et al., 2011; Pehrson et al., 1997; Posavec Marjanovic et al.,
2017; Sun and Bernstein, 2019); however, the functional signif-
icance and the underlying mechanism of the alternative
splicing of H2afy have not been fully understood. In this study,
we report alternative splicing of H2AFY as a downstream
target of mutant U2AF1(S34F) that results in impaired B lym-
phopoiesis. Our data further suggest that H2AFY occupancy
at the promoter region of Ebf1 may directly regulate its expres-
sion as a potential mechanism underlying B cell deficiencies
observed in U2AF1(S34F) mice and MDS patients with a
U2AF1 mutation. H2AFY is generally considered a transcrip-
tion repressor because it was found to predominantly localize
in inactive X chromosome and heterochromatin (Buschbeck
et al., 2009; Changolkar and Pehrson, 2006; Costanzi and
Pehrson, 1998). However, our data show that loss of H2afy
correlates with reduced Ebf1 expression, similar to several
studies that reported positive transcriptional regulation by
H2AFY in a context-dependent manner (Changolkar and Pehr-
son, 2006; Chen et al., 2014; Gamble et al., 2010; Pehrson
et al., 2014; Sun et al., 2018), including one report that showed
reduced Ebf1 expression in fetal liver cells lacking both
macroH2A1 and macroH2A2 (i.e., H2afy and H2afy2, respec-
tively) (Pehrson et al., 2014). Of the two isoforms of H2afy,
expression of H2AFY1.1 in H2afy-null and U2AF1(S34F)
mouse bone marrow cells consistently rescued reduced B
cells. Taken together, our data identify a unique role of mutant
U2AF1 and its alternative splicing target, H2AFY, in B cell
development.
Reduced B cells and B cell precursors in MDS patients have
been previously recognized in MDS (Liu et al., 2020; Ogata
et al., 2006; Reis-Alves et al., 2015; Sternberg et al., 2005).
However, our understanding of the genetic causes of reduced
B cells and B cell precursors in MDS patients is incomplete.
In line with our data implicating a role for U2AF1 mutations in
B cell abnormalities in MDS, SF3B1 mutations were found to
be present in pro-B cells from MDS patients, directly impli-
cating splicing factor mutations in cell-intrinsic B cell alterations
(Mortera-Blanco et al., 2017). Mice expressing mutant SRSF2
(Kim et al., 2015b) or SF3B1 (Obeng et al., 2016) also show B
cell deficiencies, suggesting the possibility that B cell defi-
ciencies are not limited to U2AF1-mutated MDS but occur
broadly in the pathophysiology of spliceosome gene-mutated
MDS. B cell deficiencies and/or defective B cell development
may not directly affect myeloid disease progression of MDS
but could contribute to increased infectious complications in
MDS (Mortera-Blanco et al., 2017). Future studies could test
whether modulating the expression of specific splice isoforms
(e.g., H2AFY1.1) using antisense oligonucleotides could
improve cytopenias and morbidities in preclinical models and
ultimately in patients with MDS.





Detailed methods are provided in the online version of this paper
and include the following:




B Data and code availability
d EXPERIMENTAL MODEL AND SUBJECT DETAILS
B Animal models
B Human MDS samples and healthy donor bone marrow
samples
B Mouse bone marrow transplant and competitive repo-
pulation assays
B Transplant of U2AF1(WT) and U2AF1(S34F) mouse
bone marrow
d METHOD DETAILS
B Cell staining and flow cytometry
B Mouse mature lineage cell distribution
B Mouse stem and progenitor cells
B Human B cells
B Intracellular mouse and human EBF1 protein staining
for flow cytometry
B Western blotting of H2AFY
B Colony forming assays
B Nanostring assay and analysis
B Limiting dilution assay for assessing functional CLP
frequencies
B Cloning of H2AFY1.1 and H2AFY1.2 expression lenti-
virus plasmids and virus generation
B H2AFY1.1/H2AFY1.2 complementation assay




B Abelson transformed pre-B cells and H2AFY ChIP-
qPCR
d QUANTIFICATION AND STATISTICAL ANALYSIS
SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.
celrep.2021.109626.
ACKNOWLEDGMENTS
The authors thank Drs. Timothy Ley and Dan Link for helpful scientific discus-
sions and Drs. Li Ding and Reyka Jayasinghe for discussion of H2AFY expres-
sion in various datasets. The authors thank Drs. Matthew Ndonwi, Shawn Jin,
Tianjiao Wang, Sara Arenas, and Christian Rosa-Birriel for technical assis-
tance. Dr. Kim Trinkaus at the Siteman Cancer Center Biostatistics Shared
Resource provided helpful advice regarding the limiting dilution assay. This
work was supported by the Siteman Cancer Center (Cancer Biology Pathway
pre-doctoral fellowship T32 CA113275 and P30 CA091842 to S.P.K.) and
grants from the Edward P. Evans Foundation (to M.J.W.), the Taub Foundation
(to M.J.W.), the Lottie Caroline Hardy Trust (to M.J.W.), an NIH/NCI grant (K12
CA167540; to B.S.W., M.O.A., and C.L.S.), and a Clinical and Translational
Award from the NIH National Center for Advancing Translational Sciences
(UL1 TR000448 to B.S.W.). Support for procurement of human samples and
research was provided by the Genomics of AML Program Project of the NCI
(P01 CA101937) and the Specialized Program of Research Excellence in
AML (P50 CA171963). Core services were provided by the Siteman Cancer
Center Tissue Procurement Core, the Flow Cytometry Core, the Genome
Technology Access Center, and the Division of Comparative Medicine at
Washington University School of Medicine. The Siteman Cancer Center is sup-
ported in part by NCI Cancer Center Support grant P30 CA091842.
AUTHOR CONTRIBUTIONS
The study was designed by S.P.K. and M.J.W. Mouse characterization was
done by S.P.K. and M.C., and data analysis was by S.P.K., M.J.W., M.O.A.,
L.S.W., J.B., and J.R.P. Nanostring design and data generationwas performed
by B.S.W., C.L.S., S.N.S., and M.J.W. RNA-seq was done by S.P.K. Bio-
informatic analysis of data was performed by S.P.K., S.N.S., B.S.W., and
M.J.W. S.P.K., J.S., R.N., and T.A. analyzed clinical samples. S.P.K. and
M.J.W. wrote the paper.
DECLARATION OF INTERESTS
R.N. is a paid consult for Biocomposites, DePuy, Medical Compression Sys-
tems, Inc., Mirus, Cardinal Health, Halyard, Medtronic, and Smith & Nephew.
R.N. receives research support from Biomet, Medical Compressions Systems,
Stryker, DePuy, and Smith &Nephew. The other authors declare no competing
interests.
Received: February 19, 2019
Revised: May 19, 2021
Accepted: August 5, 2021
Published: August 31, 2021
REFERENCES
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REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
CD34 FITC Thermo Fisher Scientific Cat# 11-0341-82; RRID:AB_465021
CD11b PE Thermo Fisher Scientific Cat# MA1-10082; RRID:AB_11154207
c-Kit APC-e780 Thermo Fisher Scientific Cat# 47-1172-82; RRID:AB_1582226
c-Kit APC Thermo Fisher Scientific Cat# 17-1172-82; RRID:AB_469433
CD115 PE Thermo Fisher Scientific Cat# 12-1152-81; RRID:AB_465807
GR1 APC-e780 Thermo Fisher Scientific Cat# 47-5931-82; RRID:AB_1518804
B220 PerCP-cy5.5 Thermo Fisher Scientific Cat# 45-0452-82; RRID:AB_1107006
CD3e APC Thermo Fisher Scientific Cat# A18605; RRID:AB_2535395
FLT3 APC Thermo Fisher Scientific Cat# 17-1351-82; RRID:AB_10717261
SCA1 PerCP-cy5.5 Thermo Fisher Scientific Cat# 45-5981-82; RRID:AB_914372
CD45.2 FITC Thermo Fisher Scientific Cat# 11-0454-85; RRID:AB_465062
CD16/32-unconjugated Thermo Fisher Scientific Cat# 14-0161-86; RRID:AB_467135
NK1.1 PerCP-cy5.5 Thermo Fisher Scientific Cat# 45-5941-82; RRID:AB_914361
CD11c PerCP-cy5.5 Thermo Fisher Scientific Cat# 45-0114-82; RRID:AB_925727
CD3e PerCP-cy5.5 Thermo Fisher Scientific Cat# 45-0031-82; RRID:AB_2534299
IgD e450 Thermo Fisher Scientific Cat# 48-5993-82; RRID:AB_1272202
Ter119 BV605 Biolegend Cat# 116239; RRID:AB_2562447
CD16/32 BV421 Biolegend Cat# 101332; RRID:AB_2650889
GR1 BV605 Biolegend Cat# 108440; RRID:AB_2563311
B220 BV605 Biolegend Cat# 103243; RRID:AB_11203907
CD3e BV605 Biolegend Cat# 145-2C11; RRID:AB_2565842
SCA1 PE-Cy7 Biolegend Cat# 108114; RRID:AB_493596
CD150 PE Biolegend Cat# 115904; RRID:AB_313683
CD48 PE-Cy7 Biolegend Cat# 103423; RRID:AB_2075050
CD45.1 BV421 Biolegend Cat# 110732; RRID:AB_2562563
CD45.2 BV421 Biolegend Cat# 109832; RRID:AB_2565511
Streptavidin BV421 Biolegend Cat# 405225
CD41 BV605 Biolegend Cat# 133921, AB_2563933
IL7RA Biotin Biolegend Cat# 135006, AB_2126118
EBF1 PE BD Biosciences Cat# 565494; RRID:AB_2739263
IgM APC Thermo Fisher Scientific Cat# 17-5790-82; RRID:AB_469458
CD19 PE-Cy7 Thermo Fisher Scientific Cat# 25-0193-81; RRID:AB_657664
Ly6D FITC BD Biosciences Cat# 561148; RRID:AB_10562197
CD43 BV510 BD Biosciences Cat# 563206; RRID:AB_2738069
CD20 PerCP-Cy5.5 BD Biosciences Cat# 560736; RRID:AB_1727451
CD38 PE-Cy7 Thermo Fisher Scientific Cat# 25-0389-41; RRID:AB_1724065
CD34 BV421 BD Biosciences Cat# 562577; RRID:AB_2687922
CD10 BV605 BD Biosciences Cat# 562978; RRID:AB_2737929
CD19 APC BD Biosciences Cat# 555415; RRID:AB_398597
CD14 FITC BD Biosciences Cat# 555397; RRID:AB_395798
CD56 FITC BD Biosciences Cat# 562794; RRID:AB_2737799
CD3 FITC Thermo Fisher Scientific Cat# 11-0038-42; RRID:AB_2043831
Human BD Fc Block BD Biosciences Cat# 564219; RRID:AB_2728082
(Continued on next page)
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H2AFY (total) Cell Signaling Technology Cat# 8551; RRID:AB_2797647
Histone H3 Abcam Cat# ab1791; RRID:AB_302613
Anti-rabbit IgG HRP Cell Signaling Technology Cat# 7074; RRID:AB_2099233
Anti-mouse IgG HRP Cell Signaling Technology Cat# 7076; RRID:AB_330924
H2AFY antibody Abcam Cat# ab37264; RRID:AB_883064
Normal Rabbit IgG Millipore Sigma Cat# 12-370; RRID:AB_145841
Biological samples
Human MDS samples This paper Washington University
Human healthy donor bone marrow samples This paper Washington University
Chemicals, peptides, and recombinant proteins
Penicillin-Streptomycin Thermo Fisher Scientific Cat# 15140122
Iscove’s Modified Dulbecco’s Medium Thermo Fisher Scientific Cat# 12440061
DMEM Thermo Fisher Scientific Cat# 11960077
RPMI 1640 Medium Thermo Fisher Scientific Cat# 11875085
GlutaMAX Supplement Thermo Fisher Scientific Cat# 35050061
MEM Non-Essential Amino Acids Solution Thermo Fisher Scientific Cat# 11140050
Sodium Pyruvate (100 mM) Thermo Fisher Scientific Cat# 11360070
HEPES (1 M) Thermo Fisher Scientific Cat# 15630080
2-Mercaptoethanol Thermo Fisher Scientific Cat# 21985023
Dulbecco’s PBS Thermo Fisher Scientific Cat# 14190136
HBSS Thermo Fisher Scientific Cat# 14175079
0.5M EDTA, pH 8.0 Corning Cat# 46-034-CI
Fetal Bovine Serum VWR Cat# 89510-194
L-glutamine Thermo Fisher Scientific Cat# 25030081
RetroNectin Recombinant Human Fibronectin Fragment Takara Cat# T100A
SuperSignal West Pico PLUS Chemiluminescent
Substrate
Thermo Fisher Scientific Cat# 34580
SuperSignal West Femto Maximum Sensitivity Substrate Thermo Fisher Scientific Cat# 34095
Recombinant Murine Il7 Peprotech Cat# 217-17
Recombinant Murine SCF Peprotech Cat# 250-03
Recombinant Murine TPO Peprotech Cat# 315-14
Recombinant Murine Il3 Peprotech Cat# 213-13
Recombinant Murine FLT3 ligand Peprotech Cat# 250-31L
Bovine Serum Albumin solution Millipore Sigma Cat# A9576-50ML
Wright Giemsa Solution Fucillo Millipore Sigma Cat# 64571-75
StemPro-34 SFM Thermo Fisher Scientific Cat# 10639011
4–15% Mini-PROTEAN TGX Precast Protein Gels Biorad Cat# 4561086
Precision Plus Protein Dual Color Standards Biorad Cat# 1610374
Hybond 0.45 PVDF GE Healthcare Cat# 10600023
625 ppm doxycycline chow TestDiet Custom ordered
doxycycline hyclate Millipore Sigma D9891-1G
Critical commercial assays
MethoCult M3630 Stemcell Technology Cat# 03630
BD Cytofix/Cytoperm BD Biosciences Cat# 554714
CD117 (c-Kit) MicroBeads Miltenyi Biotec Cat# 130-091-224
SuperScript IV First-Strand Synthesis System Thermo Fisher Scientific Cat# 18091050
NucleoSpin RNA XS MACHEREY-NAGEL Cat# 740902.10
QIAquick PCR Purification Kit QIAGEN Cat# 28104
(Continued on next page)
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Protein A Dynabeads Thermo Fisher Scientific Cat# 10001D
RNA 6000 Nano Kit Agilent Cat# 5067-1511
SYBR Green PCR Master Mix Thermo Fisher Scientific Cat# 4309155
SMARTer Ultra Low RNA kit Clontech Cat# 634890
miRNeasy kit QIAGEN Cat# 217004
SYBR green PCR Master mix Thermo Fisher Scientific Cat# 4309155
Deposited data
BLP-RNA-seq This paper GEO: GSE125118
Ebf1 knockout RNA-seq Jensen et al., 2018 GEO: GSM2879293
B cell development RNA-seq Heng et al., 2008 GEO: GSE109125
RNA-seq analysis code This paper Github; https://github.com/sridnona/
H2afy_creports
Western blot This paper Mendeley Data, V1, https://doi.org/
10.17632/7xvb8bx5ct.1
Experimental models: Cell lines
293T ATCC Cat# CRL-3216
K562 ATCC Cat# CCL-243
OP9 ATCC Cat# CRL-2749
H2afy+/+ pre-B Abelson cells This paper N/A
H2afy/ pre-B Abelson cells This paper N/A
Experimental models: Organisms/strains
Mouse: H2afy/ Changolkar et al., 2007 N/A
U2AF1(S34F) Shirai et al., 2015 N/A
Rosa26-RTTA Shirai et al., 2015 N/A
CD45.1 NCI B6- Ly5.1/Cr Charles River Cat# 564
CD45.1/CD45.2 This paper N/A
Oligonucleotides
H2afy mouse genotype forward primer:
TCTTTGCAAGGGTCAGACG
Changolkar et al., 2007 N/A
H2afy mouse genotype reverse primer 1:
ACTGGAGACAGCGCATTACC
Changolkar et al., 2007 N/A
H2afy mouse genotype reverse primer 2:
CAACATAACCACCATGATCTCG
Changolkar et al., 2007 N/A
Ebf1 qRT-PCR forward primer:
ATGAAGAGGTTGGATTCTG
Yang et al., 2014 N/A
Ebf1 qRT-PCR reverse primer:
GCAGTTATTGTGTGATTCCT
Yang et al., 2014 N/A
Gapdh RT-PCR forward primer:
TGCACCACCAACTGCTTAG
Shirai et al., 2015 N/A
Gapdh RT-PCR reverse primer:
GGATGCAGGGATGATGTTC
Shirai et al., 2015 N/A
Ebf1-ChIP-primer A-forward:
GAGGCTCGCTGATTGAAAAC
Jiang et al., 2011 N/A
Ebf1-ChIP- primer B-forward:
GGATCTATTTATTGTCTGGGACGA
Jiang et al., 2011 N/A
Ebf1-ChIP- primer C-forward:
AAAGGCAATTCACCCAGATG
Jiang et al., 2011 N/A
Ebf1-ChIP- primer D-forward:
GAGGATCCTGGTGGATCAGA
Jiang et al., 2011 N/A
Ebf1-ChIP- primer E-forward:
ACTTCTGGAGAGTAGTGACCGAGT
Jiang et al., 2011 N/A
(Continued on next page)






Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Matthew
J. Walter (mjwalter@wustl.edu).
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Ebf1-ChIP- primer F-forward:
CGCTCCTTCCAGTTTAGACG
Jiang et al., 2011 N/A
Ebf1-ChIP- primer G-forward:
AAAAACTTGCCTGGTTGTGG
Jiang et al., 2011 N/A
Ebf1-ChIP-primer A-reverse:
AAAGGGCCTGTTTCCCTAAA
Jiang et al., 2011 N/A
Ebf1-ChIP-primer B-reverse:
GAAAACTGAAGAAGAGGGTGACAG
Jiang et al., 2011 N/A
Ebf1-ChIP-primer C-reverse:
GAGAAGGCAGTGATGGTGGT
Jiang et al., 2011 N/A
Ebf1-ChIP-primer D-reverse:
GTGGGTGGGTGTATTCCAAG
Jiang et al., 2011 N/A
Ebf1-ChIP-primer E-reverse:
ATACGACTTTAGTAGACCGCAAGG
Jiang et al., 2011 N/A
Ebf1-ChIP-primer F-reverse:
GTCATCCTTCCGCCTTATCA
Jiang et al., 2011 N/A
Ebf1-ChIP-primer G-reverse:
GGGCTGGAGTTTCCTTTTGT
Jiang et al., 2011 N/A
Recombinant DNA
H2AFY1.1 cDNA Chadwick and Willard, 2001 Addgene 45166
H2AFY1.2 cDNA Chadwick and Willard, 2001 Addgene 45168
Lenti-MND-IRES-GFP-Flag Okeyo-Owuor et al., 2015 N/A
pMD-G Okeyo-Owuor et al., 2015 N/A
pMD-Lg Okeyo-Owuor et al., 2015 N/A
REV Okeyo-Owuor et al., 2015 N/A
Software and algorithms
nSolver Analysis Software Nanostring https://www.nanostring.com/products/
analysis-solutions/ncounter-analysis-
solutions/nsolver-data-analysis-support/
HISAT2 v.2.0.6 Kim et al., 2015a http://daehwankimlab.github.io/hisat2/
HTseq v.0.11.0 Anders et al., 2015 https://htseq.readthedocs.io/en/
release_0.11.0/
Voom Law et al., 2014 https://www.rdocumentation.org/
packages/limma/versions/3.28.14/
topics/voom
EdgeR Robinson et al., 2010 https://bioconductor.org/packages/
release/bioc/html/edgeR.html
DESeq2 Love et al., 2014 https://bioconductor.org/packages/
release/bioc/html/DESeq2.html
ELDA Hu and Smyth, 2009 http://bioinf.wehi.edu.au/software/elda/
FastQC The Babraham Institute https://www.bioinformatics.babraham.
ac.uk/projects/fastqc
STAR Dobin et al., 2013 https://github.com/alexdobin/STAR
StringTie v.1.3.3 Pertea et al., 2015 https://github.com/gpertea/stringtie
Flowjo v.10.6 Treestar RRID:SCR_008520
VarSCAn Koboldt et al., 2012 http://varscan.sourceforge.net/





Abelson-transformed pre-B cells (H2afy/ and H2afy+/+) are available upon request.
Data and code availability
d RNA-seq data have been deposited at GEO and are publicly available as of the date of publication. Accession numbers are
listed in the Key resources table. Original western blot images have been deposited at Mendeley and are publicly available
as of the date of publication. The DOI is listed in the Key resources table.
d This paper analyzes existing, publicly available data. These accession numbers for the datasets are listed in the Key resources
table.
d All original code has been deposited at GitHub and is publicly available as of the date of publication. DOIs are listed in the Key
resources table.
d Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animal models
All mouse procedures were performed according to protocols approved by Institutional Animal Care and Use Committee at Wash-
ington University in St. Louis. H2afy knock-out mice were generated and described previously by Pehrson and colleagues (Changol-
kar et al., 2007). Transgenic U2AF1(WT) and U2AF1(S34F) mice were described previously (Shirai et al., 2015). Transgenic
U2AF1(WT) or U2AF1(S34F) mice were crossed with Rosa26-rtTA mice, and double transgenic mice with a single copy of a
U2AF1 transgene and an rtTA transgene were used for all experiments. Transgenic mouse colonies were maintained by breeding
heterozygous, double transgenic [U2AF1(WT)/rtTA or U2AF1(S34F)/rtTA] mice to wild-type C57BL/6 mice. Doxycycline was admin-
istered via doxycycline-containing rodent chow (625 ppm doxycycline, pico 5053 base, TestDiet). All of the mice used in the exper-
iments were backcrossed into the C57BL/6 background at least 10 times. For all experiments, wild-type littermate controls were
used.
Human MDS samples and healthy donor bone marrow samples
The use of human MDS samples and healthy donor bone marrow samples was approved by the Washington University School of
Medicine Institutional Review Board and with patients’ consent for sample use. Studies were performed in accordance with the
Declaration of Helsinki. Bonemarrow cells were frozen and thawed for experiments. Clinical and genetic information for patient sam-
ples is included in Table S4.
Mouse bone marrow transplant and competitive repopulation assays
Bone Marrow Transplant of H2afy+/+, H2afy+/ or H2afy/ Cells
To generate mice for each experiment, one million whole bone marrow cells from threeH2afy+/+,H2afy+/ orH2afy/ female mice
were pooled (CD45.2) and transplanted into at least five lethally irradiated (1,100 rads, cesium-137 irradiator) wild-type congenic fe-
male recipient mice (CD45.1, NCI B6- Ly5.1/Cr, Charles River). Donor mice were between 8 and 12weeks of age, and recipients were
7-12 weeks of age. Competitive repopulation assays were performed by mixing ‘‘test’’ whole bone marrow cells from three H2afy+/+
or H2afy/ female mice pooled (CD45.2) in equal proportions with ‘‘competitor’’ whole bone marrow cells from three female wild-
type congenic mice (CD45.1/45.2, C57BL/6) pooled, and transplant of two million mixed cells into lethally irradiated (1,100 rads, ce-
sium-137 irradiator) wild-type congenic female recipient mice (CD45.1, C57BL/6). Donor mice were between 6 and 12 weeks of age,
and recipients were 7-12 weeks of age. Male donor and recipient mice were used for empty-vector, H2AFY1.1, and H2AFY1.2
expression experiments.
Transplant of U2AF1(WT) and U2AF1(S34F) mouse bone marrow
To generate mice for experiments, one million whole bone marrow cells from three female U2AF1(WT)/rtTA or U2AF1(S34F)/rtTA
pooled (CD45.2) were transplanted into ten lethally irradiated (1,100 rads, cesium-137 irradiator) wild-type congenic recipient female
mice (CD45.1, NCI B6-Ly5.1/Cr, Charles River). Donor mice were between 8 and 12 weeks of age and recipients were 7-12 weeks of
age. Male donor and recipient mice were used for empty-vector, H2AFY1.1, and H2AFY1.2 expression experiments.
METHOD DETAILS
Cell staining and flow cytometry
Red blood cells of peripheral blood, bone marrow, or spleen were lysed by 5 minutes incubation in the ACK lysis buffer on ice. Cells
were treated with anti-mouse CD16/32 or human Fc block (BD Biosciences, Cat# 564219) and stained with the indicated combina-
tions of the following antibodies:




Mouse mature lineage cell distribution
CD11b PE (clone M1/70), CD115 PE (clone AFS98), Gr-1 APC-e780 or BV605 (clone RB6-8C5), B220 PerCP-cy5.5 or BV605 (clone
RA3-6B2), CD3 APC or BV605 (clone 145- 2C11), CD45.1 BV421 (clone A20), and CD45.2 FITC or BV421 (clone 104).
Mouse stem and progenitor cells
Lineage-BV605 (Lin): B220+, CD3e+, Gr-1+, Ter-119+, or CD41+; KLS: Lin–, Sca-1+, c-Kit+; KLS-SLAM: Lin–, SCA-1+, c-Kit+, CD150+,
CD48-; GMP: Lin–, SCA-1+, c-Kit+, CD34+, CD16/32+; CMP: Lin–, SCA-1–, c-Kit+, CD34+, CD16/32–; MEP: Lin–, SCA-1–, c-Kit+,
CD34–, CD16/32–; CLP: Lin-, SCA-1+, c-Kit+, FLT3+, IL7R⍺+; ALP: Lin-, SCA-1+, c-Kit+, FLT3+, IL7R⍺+, Ly6D-; BLP: Lin-, SCA-1+,
c-Kit+, FLT3+, IL7R⍺+, Ly6D+; Hardy Fraction A: B220+, NK1.1-, CD3e-, CD11c-, IgM-, IgD-, CD19-, Ly6D+; Hardy Fractions B-C:
B220+, NK1.1-, CD3e-, CD11c-, IgM-, IgD-, CD19+, CD43+; Hardy Fractions D: B220+, NK1.1-, CD3e-, CD11c-, IgM-, IgD-, CD19+,
CD43-; Hardy Fractions E: B220+, NK1.1-, CD3e-, CD11c-, IgM+, IgD-; Hardy Fractions F: B220+, NK1.1-, CD3e-, CD11c-, IgM+, IgD+.
Human B cells
CD19+ B cells: CD3-, CD14-, CD56-, CD19+; CLP: CD3-, CD14-, CD56-, CD19+, CD19-, CD20-, CD34+, CD10+; Pro-B: CD3-, CD14-,
CD56-, CD19+, CD34+; Pre-BI: CD3-, CD14-, CD56-, CD19+, CD38+, CD34-; Pre-BII: CD3-, CD14-, CD56-, CD19+, CD20+
Analysis was performed using a Gallios (Beckman Coulter) and data were analyzed using FlowJo version 10.4.2 (Treestar).
Intracellular mouse and human EBF1 protein staining for flow cytometry
Cells were stained for cell surfacemarkers as described above and then fixed and permeabilized using the Cytofix/Cytoperm and the
Permeabilization Buffer Plus kit (BD Pharmingen), respectively, according to the manufacturer’s instructions. Intracellular EBF1 was
stained with primary mouse EBF1 antibody conjugated with PE (1:100 dilution, Clone T26-818, BD Pharmingen) for 20minutes at 4C
and analyzed by flow cytometry. Themean fluorescence intensity was calculated for the PE signal. Human andmouse EBF1 proteins
are 100% homologous at the amino acid level, and we determined the cross-reactivity of the anti-mouse EBF1 antibody against hu-
man EBF1 using EBF1-negative 293T cells transiently transfected with human EBF1 expression plasmid.
Western blotting of H2AFY
Histone extracts were prepared using EpiQuik Total Histone Extraction Kit (EpiGentek) according to the manufacturer’s instructions.
Proteins were separated by SDS-PAGE using Mini-PROTEAN gels (4%–15%, Biorad) and transferred to PVDF membranes (EMD
Millipore) at 20V overnight at 4C. Membranes were incubated in 5% nonfat dry milk in Tris-buffered saline with 0.1% Tween-20
((TBST) for 1 hour at room temperature and were probed with primary antibodies (H2AFY: reacting to both human and mouse,
Cell Signaling Technology #8551; histone H3: Abcam ab1791) in 3% nonfat dry milk TBST for 2 hours at room temperature (Histone
H3) or 16 hours at 4C (H2AFY). Membranes were rinsed 4 times in TBST for 5 minutes and then incubated with horseradish-perox-
idase–conjugated anti-rabbit (1:10000; Cell Signaling Technology #7074) or anti-mouse (1:10000; Cell Signaling Technology #7076)
secondary antibodies for 1 hour at room temperature. Membranes were then washed 4 times in TBST for 5 minutes each time, and
ECL (SuperSignal West Pico PLUS, Thermo Fisher) was applied for 1 minute. Membranes were imaged with a myECL Imager
(Thermo Fisher).
Colony forming assays
Bone marrow cells were harvested and lysed to remove red cells. One hundred thousand whole bone marrow cells or two hundred
thousand bone marrow cells sorted for GFP were seeded in methylcellulose media (M3630, Stem Cell Technologies) to detect CFU-
Pre-B per the manufacturer’s instructions. To induce transgenic U2AF1(WT) or U2AF1(S34F) expression, doxycycline hyclate
(75ng/mL, Millipore Sigma) in water was added to the media before cell seeding. CFU-Pre-B colonies were counted on days 7–8.
Nanostring assay and analysis
Samples for NanoString were generated similar to experiments previously described for transgenic U2AF1(S34F) and U2AF1(WT)
mouse experiments (Shirai et al., 2015). Transgenic mouse donor cells (CD45.2, 1x10̂ 6 cells from 2-3 mice pooled) from a mixed
C57BL/6 3 129S4Sv/Jae strain (Shirai et al., 2015) were transplanted into lethally irradiated wild-type F1 (C57BL/6 3 129S4Sv/
Jae) recipient mice (CD45.1/CD45.2). Following at least 6 weeks of bone marrow engraftment, transgene induction was performed
in vivo for 5 days with 625 ppm doxycycline chow. U2AF1(S34F)- or U2AF1(WT)-expressing lineage specific cells were FACS sorted
from bone marrow using a congenic marker (CD45.2) and the staining schemes as described above. RNA was extracted from sorted
cells using the miRNeasy kit (QIAGEN), and a custom-designed Nanostring assay was performed using 100 ng of bulk RNA per the
manufacturer’s protocol (Nanostring Technologies). The Nanostring probesets were designed to query previously identified splice
junctions perturbed by U2AF1(S34F) expression in mice, as defined by RNA-seq (Shirai et al., 2015). For each splice junction, a re-
porter/capture probe pair was constructed in such a way that the two probes targeted (were complementary to) the two exons on
either side of the splice junction.
RCC files from Digital Analyzer were processed using nSolver Analysis Software (Nanostring) and custom R scripts to extract raw
counts for downstream analysis. Log2 fold change for each probe was calculated by processing the raw counts using Voom (Law
et al., 2014) followed by EdgeR (Robinson et al., 2010).




Limiting dilution assay for assessing functional CLP frequencies
One thousand OP9 cells were seeded onto 96 well plates a day before CLP sorting. On the next day, bone marrow cells were har-
vested and enriched for c-Kit+ cells using CD117 MicroBeads on the autoMACS Pro Separator (Miltenyi Biotec). Subsequently, cells
were stained, as described above, and 1, 4, 16, or 32 cells of GFP+ CLPs were isolated (Moflo plate sorter, Beckman Coulter) directly
into 96 well plates with OP9 feeder cells in RPMI1640 media containing 1% glutamine (GIBCO), 1%MEM non-essentail amino acids
(GIBCO), 1% sodium pyruvate (GIBCO), 1%HEPES (GIBCO), 55 mM b-mercaptoethanol (GIBCO), 20 ng/mL SCF (Peprotech), 20 ng/
mL FLT3 ligand (Peprotech), and 20 ng/mL IL7 (Peprotech). All of the growth factors were murine recombinant proteins. At day 3,
media was replenished and at day 7, CD19+ B cells were counted by flow cytometry using a plate reader on the ZE5TMCell Analyzer
(Bio- rad). Limiting dilution analysis was performed using the ELDA program (http://bioinf.wehi.edu.au/software/elda/) (Hu and
Smyth, 2009).
Cloning of H2AFY1.1 and H2AFY1.2 expression lentivirus plasmids and virus generation
cDNA sequences ofH2AFY1.1 and 1.2were obtained from Addgene [H2AFY1.1 #45166, H2AFY1.2 # 45168, (Chadwick andWillard,
2001)] and were cloned into a lenti-MND-IRES-GFP-Flag vector as described previously (Okeyo-Owuor et al., 2015). Lentivirus was
generated in 293T cells (ATCC, CRL-3216) with the packaging plasmids pMD-G, pMD-Lg and REV. Virus was tittered using K562
cells (ATCC, CCL243).
H2AFY1.1/H2AFY1.2 complementation assay
H2AFY1.1 orH2AFY1.2was re-expressed either inH2afy null or in U2AF1(S34F) hematopoietic cells. A day before transduction, a 24-
well untreated plate was coatedwith Retronectin (T100B, Clontech) per themanufacturer’s instructions overnight at 4C.Whole bone
marrow cells from H2afy null or U2AF1(S34F) mice were c-Kit enriched using CD117 MicroBeads on the autoMACS Pro Separator
(Miltenyi Biotec). Cells were then transferred to a Retronectin-coated plate and control lentivirus orH2AFY1.1 or 1.2 expression lenti-
virus (MOI of 5) was added. Cells were spun at 1250G at 35C for 90 minutes. Cells were rested in an incubator for 2 hours and warm
media was added. The next day, 150,000 to 200,000 cells (CD45.2) were transplanted into lethally irradiated wild-type congenic re-
cipients (CD45.1) via retro-orbital injection. Recipients of H2afy null bone marrow cells complemented with control, H2AFY1.1 or 1.2
were bled at eachmonth tomonitor GFP+ lineage cell frequencies. At 4 months post-transplant, GFP+ CLPs were sorted for a limiting
dilution assay as outlined above. U2AF1(S34F)-recipients were bled at 4 weeks post-transplant to monitor chimerism, and treated
with 625ppm doxycycline chow for 6 months when the mice were sacrificed for bone marrow analysis.
BLP RNA collection, library preparation, and sequencing
Bone marrow cells were harvested from H2afy+/+ and H2afy/ mice of 5-12 weeks of age. Cells were enriched for c-Kit+ cells using
CD117 MicroBeads on the autoMACS Pro Separator (Miltenyi Biotec). Subsequently, cells were stained according to the staining
scheme described above, and BLPs were sorted by FACS (Moflo, Beckman Coulter) directly into the lysis buffer of NucleoSpin
RNA XS kit (MACHEREY-NAGEL). RNA was isolated per manufacturer’s instructions. Per sample, RNA equivalent of 5,000-
15,000 BLPs from 2-3 mice were pooled. Total RNA integrity and concentration were assessed using a 2100 Bioanalyzer and an
RNA 6000 Pico kit (Agilent). Library preparation was performed with 10-50ng of total RNA with a Bioanalyzer RIN score greater
than 8.0. Double stranded-cDNA was prepared using the SMARTer Ultra Low RNA kit for Illumina Sequencing (Takara-Clontech)
per manufacturer’s protocol. cDNA was fragmented using a Covaris E220 sonicator using duty cycle 10, intensity 5, cycles/burst
200, time 180 s. cDNA was blunt ended, had an A base added to the 30 ends, and then had Illumina sequencing adapters ligated
to the ends. Ligated fragments were then amplified for 12 cycles using primers incorporating unique index tags. Fragments were
sequenced on an Illumina HiSeq-3000 using single reads extending 50 bases.
RNA-seq analyses
BLPs RNA-seq
Read quality was assessed using FastQC (https://www.bioinformatics.babraham.ac.uk/projects/fastqc). Reads were mapped using
HISAT2 (version 2.0.6) (Kim et al., 2015a) against the mm9 version of the mouse genome from Ensembl consortium. Reads were
further processed using HTseq (version 0.11.0) (Anders et al., 2015). Differentially expressed genes were identified using DESeq2
(Love et al., 2014), following filtering out genes with fewer than 5 reads in the half of the samples. Differentially expressed genes
were filtered using a false discovery rate (FDR) cutoff of < 10%. TPM values were calculated using StringTie (version 1.3.3) (Pertea
et al., 2015). Gene enrichment analysis (GO ontology) was performed using Clusterprofiler (version 3.10.1) (Yu et al., 2012) against GO
processes (e.g., Cellular-Components [CC], MFMolecular Function [MF], and Biological Process [BP]). Pathway enrichment analysis
was performed using fgsea (version 1.8.0 [https://www.biorxiv.org/content/10.1101/060012v1]) and the pre-ranked function against
GO, Reactome, and MSIGDB gene sets.
Ebf1 knock-out pro-B cell RNA-seq
The data were previously reported (Jensen et al., 2018). Raw reads were processed and analyzed by the same method as the above
BLP RNA-seq dataset.




H2afy RNA expression during B cell development
Raw reads were downloaded from (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE92434). Data are assembled by the
ImmGen consortium (Heng et al., 2008). Read quality was assessed using FastQC and aligned against the mouse genome (mm9)
using STAR (Dobin et al., 2013) as specified in the ImmGen protocols (https://www.immgen.org/Protocols/ImmGenULI_RNAseq_
methods.pdf). Expression (TPM) of H2afy was calculated using StringTie (version 1.3.3) (Pertea et al., 2015).
Ebf1 qRT-PCR
BLP cells were sorted and RNA was isolated and quantified as described above. Two mice were pooled for each sample. RNA was
converted to cDNA using SuperScript IV First-Strand Synthesis System (18091050, Thermo Fisher). Ebf1 qRT-PCR [Ebf1 forward
primer 50-ATGAAGAGGTTGGATTCTG-30, reverse primer 50-GCAGTTATTGTGTGATTCCT-30, primer sequences are from (Yang et
al., 2014) and Gapdh qRT-PCR (Forward primer 50- TGCACCACCAACTGCTTAG-30, Reverse primer 50-GGATGCAGGGAT
GATGTTC-30) were performed using the SYBR Green PCR Master Mix (4309155, Thermo Fisher) on StepOnePlus (Thermo Fisher).
Individual cDNA samples were normalized to their levels of Gapdh using the delta delta Ct method.
Abelson transformed pre-B cells and H2AFY ChIP-qPCR
Viral (v)-Abl kinase-transformed pre-B cell lines were generated from H2afy+/+ and H2afy/ bone marrow cells. Bone marrow cells
from these mice were cultured with the pMSCV-v-abl retrovirus to generate stable v-abl transformed pre-B cell lines, as described
previously (Bredemeyer et al., 2006; Mainville et al., 2001). Abelson cells were cultured in DMEM (Cat# 11960077, Thermo Fisher)
media supplemented with 10% FBS, 1% penicillin-streptomycin (Cat# 15140122, Thermo Fisher), 1% sodium pyruvate (Cat#
11360070, Thermo Fisher), 1% non-essential amino acids (Cat# 11140050, Thermo Fisher), 1% L-glutamine (Cat# 25030081,
Thermo Fisher) and 0.22 mM2-mercaptoethanol (Cat# 21985023, Thermo Fisher). Cells were passaged every 2 days andmaintained
at less than 80% confluence.
ChIP was performed as previously described (Soodgupta et al., 2019). Briefly, 10 million cells in single-cell suspension was were
crosslinked with 1% formaldehyde. Chromatin was isolated and digested by shearing with sonication, and immunoprecipitation was
performed with anti-H2AFY antibody (Cat# ab37264, Abcam) or normal Rabbit IgG (12-370, Millipore Sigma) and Protein A Dyna-
beads (Cat# 10001D, Thermo Fisher). Immunoprecipitated DNA was then washed and eluted. Sheared input material and eluted
DNA were purified with QIAquick PCR purification kit (Cat# 28104, QIAGEN). Purified DNA was amplified by RT-PCR using
SybrGreen (Cat# 4309155, Thermo Fisher) on a StepOnePlus Real-Time PCR system (Thermo Fisher) and analyzed using the relative
standard curve delta delta CTmethod as described previously (Jiang et al., 2011). The primers against themouse Ebf1 promoters are
listed in Key resources table.
QUANTIFICATION AND STATISTICAL ANALYSIS
Details of statistical tests are indicated in the Figure Legends. Statistical analyses were performed using GraphPad Prism v7.00. Sig-
nificance is indicated using the following convention: *p < 0.05, **p < 0.01, ***p < 0.001. Error bars on graphs represent the standard
deviation of the mean.
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Figure S1. Related to Figure 1. Characterization of hematopoiesis upon H2afy loss.  (A) 
Western blotting of H2AFY protein levels in whole bone marrow lysates from H2afy+/+, H2afy+/- 
and H2afy-/- littermate mice. Histone H3 is included as a loading control. (B, C) Frequencies of 
hematopoietic progenitors (B) and hematopoietic stem cells (C) in bone marrow of recipients 
following transplant of H2afy+/+ and H2afy-/- bone marrow cells (n=7). KLS, c-KIT+Lineage-SCA1+; 
LT-HSC, long-term hematopoietic stem cells; ST-HSC, short-term hematopoietic stem cells; 














** ** ** ** ** 
Figure S2. Related to Figure 2. H2afy-/- B-cells have a competitive disadvantage. (A-C) A 
competitive repopulation assay was performed by transplanting bone marrow cells harvested 
from H2afy+/+ or H2afy-/- littermate mice (CD45.2+) mixed with an equal number of wild-type 
congenic competitor marrow cells (CD45.1+/CD45.2+) into lethally irradiated congenic recipients 
(CD45.1+). (A) CD45.2+ peripheral blood lineage cell frequencies at 4 months post-transplant 
(n=16). (B) CD45.2+ splenic lineage cell frequencies at 4 months post-transplant (n=15). (C) 
Frequencies of CD45.2+ hematopoietic stem/progenitor cells in the bone marrow at 4 months 
post-transplant (n=15-16). Statistical analysis by two-tailed Student’s t-test. Error bars represent 
mean ± SD, ** p<0.01, *** p<0.001.   





Figure S3. Related to Figure 4. H2afy expression is dynamically regulated during B-cell 
development. RNA expression of H2afy across B-cell development was examined through 
transcriptomic analysis (n=2-4). For the detailed analysis please see the STAR method. LT-HSC, 
long-term hematopoietic stem cell; MPP, multi-potent progenitor; CLP, common lymphoid 
progenitor; Fr., fraction; FO-B, splenic follicular B-cells. Error bars represent mean ± SD. 
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Figure S4. Related to Figure 4. Isolation of BLPs and differentially expressed genes in 
H2afy-/- BLPs significantly overlap with those in Ebf1-/- pro-B-cells. (A) Flow cytometry 
gating strategy used to isolate BLPs from H2afy-/- and H2afy+/+ mice. (B) Differentially 
expressed genes were identified from the RNA-seq data of H2afy-/- BLPs and Ebf1-/- pro-B-
cells using the same analytic pipeline. For the detailed analysis please see the STAR 
method. The p value was calculated by 1000 permutations. KLS, c-KIT+Lineage-SCA1+; CLP, 
common lymphoid progenitors; BLP, B-cell-biased lymphoid progenitors.   





















































Figure S5. Related to Figures 4F and 6E. EBF1 expression in B-cell progenitors. 
EBF1 levels were measured in B-cell progenitors using intracellular flow cytometry. (A) 
EBF1 levels in BLPs from representative mice. (B) EBF1 levels in CLPs from a 
representative MDS patient with a U2AF1 mutation, MDS patient without a spliceosome 
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Figure S6. Related to Figure 6. Expression of H2AFY isoforms in U2AF1(S34F) mouse 
hematopoietic cells and B-cell progenitor frequencies in MDS patient samples. (A, B) 
Bone marrow cells were isolated from transgenic U2AF1(S34F) mice and transduced with 
control (GFP only), H2AFY1.1- or H2AFY1.2-expressing lentivirus that co-expresses GFP. 
Bulk cells were transplanted into lethally irradiated congenic recipients. (A) Lineage 
distribution of GFP+ cells in the peripheral blood in U2AF1(S34F) mice prior to transgene 
induction. (B) Expression levels of exogenously expressed H2AFY1.1 or H2AFY1.2 relative 
to endogenous H2afy expression in sorted GFP+ peripheral blood leukocytes were analyzed 
by Western Blotting using an H2AFY antibody. (C-E) Bone marrow samples from healthy 
donors (n=12), MDS (no SF mutations) (n=6), and MDS patients with U2AF1(S34F/Y) 
mutations (n=4) were analyzed by flow cytometry. (C) Frequency of CD19+ total B-cells. (D) 
Frequency of CLP, pro-B, pre-BI, and pre-BII cells. (E) EBF1 protein expression in CLP cells 
by intracellular flow cytometry. Statistical analysis by two tailed Student’s t-test. Error bars 
represent mean ± SD, ns not significant. * p<0.05, ** p<0.01; SF mutations, splicing factor 
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** ** * 
* 
* 
Table S2. Related to Figure 4. Dysregulated mouse Reactome gene expression pathways 
in H2afy knock-out BLPs. 
 
pathway      pval       padj       ES     NES 
IRE1ALPHA ACTIVATES CHAPERONES R-HSA-
381070.1 0.0018939 0.0930541 0.696333 2.0882366 
XBP1(S) ACTIVATES CHAPERONE GENES 
DATA BASE ID RELEASE 69381038 0.0018975 0.0930541 0.6878917 2.0425796 
UNFOLDED PROTEIN RESPONSE (UPR) R-
HSA-381119.2 0.0018727 0.0930541 0.5892297 1.9618737 
INTERFERON ALPHA BETA SIGNALING R-HSA-
909733.2 0.0018975 0.0930541 0.6542249 1.9426115 
INTERLEUKIN-6 FAMILY SIGNALING R-HSA-
6783589.6 0.0018868 0.0930541 0.7945788 1.9243185 
N-GLYCAN TRIMMING IN THE ER AND 
CALNEXIN CALRETICULIN CYCLE DATABASE 
ID RELEASE 69532668 0.0018975 0.0930541 0.6575246 1.8738962 
ASPARAGINE N-LINKED GLYCOSYLATION R-
HSA-446203.4 0.0018657 0.0930541 0.4792698 1.8618184 
CALNEXIN CALRETICULIN CYCLE R-HSA-
901042.2 0.0019342 0.0930541 0.6946618 1.8528493 
INTEGRIN CELL SURFACE INTERACTIONS 
DATABASE ID RELEASE 69216083 0.0019048 0.0930541 0.6115211 1.7947236 
HEPARAN SULFATE HEPARIN (HS-GAG) 
METABOLISM DATABASE ID RELEASE 
691638091 0.0018832 0.0930541 0.5851011 1.7073831 
SRP-DEPENDENT COTRANSLATIONAL 
PROTEIN TARGETING TO MEMBRANE 
DATABASE ID RELEASE 691799339 0.0018657 0.0930541 0.5335175 1.7058964 
TRANSPORT TO THE GOLGI AND 
SUBSEQUENT MODIFICATION R-HSA-948021.2 0.0019157 0.0930541 0.4572422 1.6573055 
ER TO GOLGI ANTEROGRADE TRANSPORT R-
HSA-199977.4 0.0018248 0.0930541 0.4516034 1.6031378 
VESICLE-MEDIATED TRANSPORT R-HSA-
5653656.2 0.001845 0.0930541 0.326181 1.3680916 
CELL CYCLE, MITOTIC DATABASE ID RELEASE 
6969278 0.0022472 0.0930541 -0.3777242 -1.5786575 
CELL CYCLE CHECKPOINTS R-HSA-69620.2 0.0021322 0.0930541 -0.4465484 -1.7506764 
MITOTIC PROMETAPHASE DATABASE ID 
RELEASE 6968877 0.0021505 0.0930541 -0.4765856 -1.7874503 
RHO GTPASES ACTIVATE FORMINS R-HSA-
5663220.1 0.0021978 0.0930541 -0.5456519 -1.9100095 
MITOTIC SPINDLE CHECKPOINT R-HSA-
69618.2 0.0021739 0.0930541 -0.5706883 -1.9655958 
AMPLIFICATION OF SIGNAL FROM 
UNATTACHED KINETOCHORES VIA A MAD2 
INHIBITORY SIGNAL DATABASE ID RELEASE 
69141444 0.0021231 0.0930541 -0.6064699 -2.0361867 
AMPLIFICATION OF SIGNAL FROM THE 
KINETOCHORES 141424 0.0021231 0.0930541 -0.6064699 -2.0361867 
RESOLUTION OF SISTER CHROMATID 
COHESION R-HSA-2500257.1 0.0021598 0.0930541 -0.6020874 -2.0708675 
pval, p-value; padj, adjusted p-value; ES, enrichment score; NES, normalized enrichment score 
  
Table S4: Related to Figure 6. Clinical information for bone marrow samples from MDS 


















489513 MDS 62 na S34Y 41% BM 
688305 MDS 69 46,XY [20] S34F 44% BM 
409585 MDS 60 46,XY [20] S34F 50% BM 




S34F 39% BM 
429745 MDS 67 






NA NA BM 
178791 MDS 71 46,XY[20] NA NA BM 
312513 MDS 73 Normal NA NA BM 
364510 MDS 47 Normal NA NA BM 
229703 MDS 68 46,XY[20] NA NA BM 
204802 CMML 76 46,XY[20] NA NA BM 
Healthy-
BM-4 
Healthy 67 NA NA NA BM 
Healthy-
BM-5 
Healthy 63 NA NA NA BM 
Healthy-
BM-6 
Healthy 71 NA NA NA BM 
Healthy-
BM-7 
Healthy 66 NA NA NA BM 
Healthy-
BM-12 
Healthy 74 NA NA NA BM 
Healthy-
BM-13 
Healthy 65 NA NA NA BM 
Healthy-
BM-14 
Healthy 80 NA NA NA BM 
Healthy-
BM-15 
Healthy 58 NA NA NA BM 
Healthy-
BM-16 
Healthy 63 NA NA NA BM 
Healthy-
BM-17 
Healthy 53 NA NA NA BM 
Healthy-
BM-18 
Healthy 66 NA NA NA BM 
Healthy-
BM-19 
Healthy 71 NA NA NA BM 
 
VAF, variant allele frequency; BM, bone marrow; CMML, chronic myelomonocytic leukemia; NA, 
not applicable; MDS, myelodysplastic syndrome. 
